The FDA highlighted uncertain heart risks tied to Novo Nordisk's long-acting insulin degludec. The drug could raise by 10% the risk of unstable angina, nonfatal stroke, nonfatal heart attack and cardiovascular death, according to the initial assessment of an analysis of 16 studies. The added risk was found to be higher at 30% in a later update.

Full Story:

Related Summaries